Inhibrx Biosciences is expected to report a Q3 2026 loss of $2.50 per share on zero revenue, with the current stock price of $14.82 trading significantly below the average analyst target of $31.25. The ONE key metric investors are focused on is the research and development spending efficiency as the company advances its clinical oncology pipeline.
Supporting context suggests that the market is primarily awaiting data readouts from the INBRX-109 registrational trial in chondrosarcoma. Analysts are closely monitoring the company's cash runway to ensure liquidity extends through the anticipated 2027 clinical milestones. Management's commentary on the Phase 1 progress for INBRX-106 will also be a critical driver for near-term sentiment.